EUCTR2011-004237-14-ES进行中（未招募）不适用
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated23-Nov-11) - COMMAND-3
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects chronically infected with HCV genotype 1
- •- HCV RNA viral load ? 10,000 IU/mL
- •- No prior treatment including but not limited to interferon, ribavirin and direct-acting antivirals
- •- if no prior history of cirrhosis liver biopsy within 3 years or Fibroscan® within 1 year
- •- Body Mass Index (BMI) of 18 to 35 kg/m²
- •- Negative for HIV and Hepatitis B
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 810
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •- Evidence of decompensated liver disease
- •- Evidence of medical condition contributing to chronic liver disease other than HCV
研究者
相似试验
进行中（未招募）
1 期
Study comparing BMS-790052 (daclatasvir) to telaprevir combined with peginterferon-alfa-2a and ribavirin in untreated hepatitis C patientsChronic Hepatitis CMedDRA version: 14.1 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2011-004237-14-GBBristol-Myers Squibb International Corporation793
进行中（未招募）
不适用
Study comparing BMS-790052 (daclatasvir) to telaprevir combined with peginterferon-alfa-2a and ribavirin in untreated hepatitis C patientsChronic Hepatitis CMedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-004237-14-DKBristol-Myers Squibb International Corporation900
进行中（未招募）
不适用
Study comparing BMS-790052 (daclatasvir) to telaprevir combined withpeginterferon-alfa-2a and ribavirin in untreated hepatitis C patientsEUCTR2011-004237-14-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO900
进行中（未招募）
不适用
Study comparing BMS-790052 (daclatasvir) to telaprevir combined with peginterferon-alfa-2a and ribavirin in untreated hepatitis C patientsChronic Hepatitis CMedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-004237-14-DEBristol-Myers Squibb International Corporation900
进行中（未招募）
不适用
Study comparing BMS-790052 (daclatasvir) to telaprevir combined with peginterferon-alfa-2a and ribavirin in untreated hepatitis C patientsEUCTR2011-004237-14-ATBristol-Myers Squibb International Corporation900